Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

National Research Corporation NRC

Healthcare — Health Information Services
Dividend Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.10
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — 1 — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
43.07%

Capital & Financial Ratios

Market Cap
461.64
Revenue
140.00
Net Income
5.86
Free Cash Flow
21.64
Net Debt
82.69
Current Ratio
0.65
Debt/Equity
13.13
P/E ratio
82.24
P/S ratio
3.23
P/B ratio
69.10
Past 5Y EPS Growth
(3.68%)
This Y EPS Growth
—
Next Y EPS Growth
—
Next 5Y EPS Growth
(7.79%)
in millions of $

Dividends

Payout Ratio
0.51
Annual Dividend Rate
0.48
Annual Dividend Yield
1.26%
total individual payouts
2026 0.99
—
—
—
2025 0.72
—
—
—
—
2024 0.48
—
—
—
—
2023 0.48
—
—
—
—
—
2022 0.84
—
—
—
—
2021 0.48
—
—
—
—
2020 0.21
—
2019 0.78
—
—
—
—
2018 0.63
—
—
—
—
2017 0.40
—
—
—
—
2016 0.34
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 6.65 4.23 4.14 3.33
Receivables 12.54 11.20 11.64 13.65
Inventory — — — —
Other 0.94 0.69 0.52 0.43
24.36 19.60 20.21 22.81
2023 2024 2025 Q'26
Payables 1.30 1.19 1.17 1.33
ST’ Debt — — — —
Other 0.88 1.10 0.95 0.40
36.20 35.86 36.62 35.02
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 34.80 35.39 — —
—
’25 33.55 34.04 34.61 35.19
137.39
’24 35.31 35.02 35.82 36.91
143.06
’23 36.47 36.16 37.95 38.00
148.58
’22 38.44 37.29 37.69 38.14
151.57
’21 35.46 36.43 37.77 38.30
147.95
’20 33.86 31.17 34.01 34.77
133.81
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 7.18 1.39 — —
—
’25 6.65 (1.14) 13.76 7.18
26.45
’24 12.04 6.79 9.42 6.38
34.63
’23 7.75 8.84 9.82 11.71
38.11
’22 8.29 9.82 10.05 8.10
36.27
’21 14.41 11.16 8.70 12.07
46.34
’20 5.52 8.38 10.52 16.22
40.64
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 5.35 0.06 — —
—
’25 3.66 (4.15) 10.18 6.06
15.74
’24 7.90 1.52 7.83 1.94
19.18
’23 4.55 4.50 5.35 7.94
22.34
’22 5.75 8.48 6.07 6.14
26.43
’21 13.17 9.59 7.71 10.36
40.83
’20 4.93 7.54 9.51 14.67
36.65
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.14 (0.15) — —
—
’25 0.25 (0.01) 0.18 0.08
0.50
’24 0.27 0.26 0.24 0.28
1.04
’23 0.28 0.29 0.32 0.36
1.25
’22 0.34 0.33 0.33 0.27
1.27
’21 0.36 0.35 0.38 0.38
1.46
’20 0.46 0.30 0.37 0.32
1.45

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 30.93 37.19 16.74 9.76 — — —
Low Price
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 42.96 47.60 42.18 19.39 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 491 435 368 357 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.31 0.34 0.39 0.38 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 151.57 148.58 143.06 137.39 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 62.36% 62.30% 60.20% 61.88% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 42.82 39.96 32.69 17.85 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.25% 26.90% 22.85% 12.99% ‡‡‡ ‡‡‡ —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.80 30.97 24.78 11.60 ‡‡‡‡‡ ‡‡‡‡‡ —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.28 5.94 6.05 7.73 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.08 6.05 6.04 6.14 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ 1.28 1.26 1.05 0.50 ‡‡‡‡ ‡‡‡ —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.46 1.55 1.46 1.18 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.39) (0.64) (0.65) (0.48) ‡‡‡ ‡‡‡ —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.06 0.91 0.81 0.70 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.89 1.99 1.32 0.63 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.92 24.54 23.70 22.38 ‡‡‡‡‡ ‡‡‡‡‡ —
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 30.41 32.70 16.80 37.54 ‡‡‡‡ — —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.40 6.80 2.92 3.06 ‡‡‡ ‡‡‡ —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.47 20.65 13.37 30.03 ‡‡‡ ‡‡‡ —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.39 7.02 3.37 3.64 ‡‡‡‡ ‡‡‡‡ —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 36.63 46.72 25.11 31.80 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 36.27 38.11 34.63 26.45 ‡‡‡ ‡‡‡ —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (9.83) (15.78) (15.45) (10.71) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 26.43 22.34 19.18 15.74 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.30 (11.84) (16.26) (16.41) — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.01 29.47 57.90 75.02 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.01) 22.82 53.66 70.88 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 72.03 48.96 31.28 13.99 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.08% 24.49% 19.44% 8.45% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 41.54% 34.87% 25.89% 16.64% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 40.41% 51.18% 61.77% 49.88% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

National Research Corporation (NRC), a healthcare information services provider, trades at a steep discount, with shares implying a potential 225% upside to unanimous analyst targets amid historical lows. Despite pandemic-fueled growth peaking at $152 million in revenue by 2022, the company has faced contraction—down to $143 million in 2024—alongside 15% headcount cuts, ballooning net debt to $54 million, and eroding margins, pressuring an increasingly strained balance sheet in a high-rate environment.

A massive projected revenue explosion to $7.3 billion in 2025 (over 5,000% growth) hints at bold catalysts like acquisitions or AI-driven expansion, bolstered by insider buying and resilient free cash flow. Yet execution risks loom large, including dilution from surging share count, policy headwinds, and competition, tempering the asymmetric upside.

This watchlist contender offers measured optimism for patient investors, but demands vigilant monitoring of debt repair and growth delivery—explore the full analysis for historical trends, valuation deep dives, and scenario modeling.

Read full commentary →

National Research Corporation (NRC) Latest News

News by impact score

Fine-tune

2 Sep

3 , 3:00 PM
NRC Health Rounding earns 91.6 overall performance score in KLAS First Look evaluation. High KLAS score strengthens NRC Health product reputation and competitive standing in healthcare IT.

10 Aug

4 , 11:34 AM
NRC Health reports a record backlog that drives strong upward potential for future revenue growth and market performance. Record backlog directly signals major revenue visibility and growth trajectory for NRC Health.

3 Aug

3 , 1:53 PM
NRC stock fell 8% despite year-over-year Q2 earnings growth driven by TRCV. Earnings growth produced an immediate 8% stock drop that signals moderate short-term market pressure without altering core operations.

30 Jul

3 , 9:00 AM
NRC Health research identifies drivers of patient loyalty beyond access to care. Findings on loyalty drivers can strengthen NRC offerings and market positioning in healthcare research.

29 Jul

4 transcript , 1:01 AM
NRC Health reported strong TRCV growth in Q2 2026 earnings call despite market uncertainty. Strong TRCV growth signals significant positive momentum likely to influence NRC trajectory and investor views.

28 Jul

4 www.marketbeat.com, 6:04 PM
National Research Corporation reported Q2 results showing revenue of $37.2 million, up 4.5% year-over-year, net income of $5.1 million, and continued client retention above 95%. Management highlighted expansion in healthcare analytics platforms and reaffirmed full-year guidance amid stable demand from hospital systems. Q2 earnings and guidance directly shape near-term revenue expectations and valuation multiples for NRC.

3 , 4:00 PM
NRC Health announced second quarter 2026 financial results. Quarterly results release supplies key metrics that can shift valuation and sentiment.

19 May

3 , 9:01 AM
NRC Health launches ambient listening powered by agentic AI for leader rounding in healthcare settings, extending AI capabilities directly to frontline operations. New AI feature rollout strengthens NRC Health product line and competitive positioning without immediate broad financial effects.

13 May

3 Simply Wall St., 6:20 AM
NRC Health (NASDAQ:NRC) reported disappointing earnings, but emerging reasons for hope suggest potential recovery. Disappointing earnings pressure financial performance moderately, balanced by optimistic indicators.

1 May

3 Zacks, 10:00 AM
NRC Health's Q1 earnings fell year-over-year due to elevated operating costs. Q1 earnings decline from higher operating costs moderately impacts financial performance and investor sentiment.

29 Apr

4 GuruFocus.com, 3:10 AM
NRC Health reports record TRCV and landmark deals in Q1 2026 earnings call, propelling strong growth. Record TRCV and landmark deals represent major strategic wins boosting NRC's growth trajectory and investor sentiment.

28 Apr

3 www.marketbeat.com, 7:39 PM
National Research Corporation (NRC) released Q1 earnings call highlights detailing financial results, operational updates, and forward-looking guidance. Q1 earnings call highlights offer insights into financial performance and strategy with moderate influence on market sentiment and trajectory.

3 Business Wire, 4:00 PM
NRC Health announced first quarter 2026 financial results. Quarterly earnings disclosure impacts financial performance and market sentiment but remains routine without transformative details.

27 Apr

3 Business Wire, 11:59 AM
The Governance Institute released the 'Falling Behind' report, warning health system operations advance faster than governance. Governance lag warning in health systems may drive demand for NRC's analytics and performance tools.

15 Apr

3 Zacks, 1:15 PM
NRC Health stock surges 62% over the past year, sparking debate on whether investors should buy amid strong performance analysis. 62% stock surge highlights solid past growth with potential to moderately boost investor sentiment and market positioning.

7 Apr

3 Business Wire, 9:01 AM
Ann & Robert H. Lurie Children’s Hospital of Chicago expands partnership with NRC Health to enhance consumer insights and online reputation strategy. Partnership expansion with a prominent children's hospital strengthens NRC Health's client base and market position in healthcare analytics.

19 Mar

4 Business Wire, 8:01 AM
Piedmont names NRC Health as strategic experience partner to support mission-driven growth. Strategic partnership with Piedmont represents a major client win enhancing NRC Health's revenue potential and market positioning.

13 Mar

3 Insider Monkey, 8:05 AM
National Research Corporation (NRC) stands out as a strong investment due to its solid financial performance, consistent revenue growth, high profitability margins, strong balance sheet, and attractive valuation metrics. Positive investment analysis highlights NRC's financial strengths and growth potential, likely influencing investor sentiment moderately.

9 Mar

4 Business Wire, 4:30 PM
NRC Health's board authorized a $60 million share repurchase program to buy back outstanding shares, signaling confidence in the company's value and future prospects. A $60 million share repurchase program is a major capital allocation strategy that boosts EPS, supports stock price, and signals management confidence in long-term growth.

9 Feb

4 Zacks, 12:50 PM
National Research Corporation (NRC) reported a decline in Q4 earnings year-over-year, attributed to high client attrition rates. As a result, the company's stock fell by 27%. The loss of clients has raised concerns about NRC's future financial stability and market position. High client attrition significantly impacts future revenue and investor sentiment.

4 Feb

4 Business WireMarketBeatFortuneStockStorySimply Wall St.MarketBeatMotley FoolSimply Wall St., 8:00 AM
NRC Health has been recognized as the #1 Best in KLAS for Healthcare Experience Management for the second consecutive year. This accolade highlights NRC's commitment to enhancing patient experiences and improving healthcare outcomes through its innovative solutions. The KLAS rankings are based on feedback from healthcare providers, emphasizing NRC's strong performance in the market. Achieving the top KLAS ranking is likely to enhance NRC's competitive position and market sentiment significantly.

3 Simply Wall St., 5:17 AM
National Research Corporation (NRC) has been evaluated for its fair value, considering various financial metrics and market conditions. Analysts have assessed the company's growth potential and competitive positioning within the healthcare market. The analysis highlights NRC's strengths and weaknesses, providing insights into its future performance and investment viability. Moderate influence on financial performance and competitive positioning is expected based on the fair value assessment.

3 Feb

4 transcript www.marketbeat.com, 8:08 PM
National Research Corporation (NRC) reported its Q4 earnings, highlighting strong revenue growth and increased demand for its services. The company emphasized its strategic initiatives aimed at enhancing customer experience and expanding market reach. Key metrics showed improvement in client retention and satisfaction scores, indicating a positive trend in operational performance. NRC's leadership expressed optimism about future growth prospects, driven by ongoing investments in technology and innovation. Strong revenue growth and strategic initiatives indicate significant potential for future performance.

4 Business Wire, 9:00 AM
NRC Health reported its fourth quarter 2025 results, highlighting significant growth in revenue and an increase in customer satisfaction metrics. The company attributed its success to enhanced service offerings and strategic partnerships. Additionally, NRC announced plans for future investments in technology to further improve healthcare analytics and patient engagement. Overall, the results exceeded market expectations, positioning NRC favorably for continued growth in the upcoming year. Significant growth in revenue and strategic investments indicate a strong potential for future performance.

30 Jan

4 www.marketbeat.com, 4:03 AM
National Research Corporation (NRC) highlights the benefits of combining Net Promoter Score (NPS) with Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) to enhance patient experience and improve reimbursement rates. This strategic pairing is expected to provide healthcare organizations with deeper insights into patient satisfaction and operational performance, ultimately leading to better financial outcomes. Combining NPS with HCAHPS could significantly enhance patient experience metrics and reimbursement strategies, impacting NRC's market position.

10 Jan

4 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 7:42 AM
National Research Corporation (NRC) has achieved a significant milestone with 51% ownership held by institutional investors, indicating strong institutional backing. This level of ownership suggests confidence in NRC's business model and future prospects, potentially enhancing its market credibility and stability. The support from institutional investors may also provide NRC with greater access to capital and resources for growth initiatives. Strong institutional backing is likely to enhance NRC's market credibility and provide access to capital for growth.

8 Dec

3 , 8:42 AM
Concerns have arisen among investors regarding National Research Corporation's returns on capital. Analysts are questioning the company's ability to generate adequate returns relative to its capital investments, which could impact investor confidence and future performance. The scrutiny comes amid broader market trends and competitive pressures that may affect NRC's operational effectiveness and financial health. Investor concerns about returns on capital may moderately influence financial performance and market sentiment.

2 Dec

4 Business Wire, 9:00 AM
NRC Health has partnered with Mosaic Life Care to enhance patient experience across the Midwest. This collaboration aims to leverage NRC's expertise in patient insights and analytics to improve healthcare delivery and patient satisfaction. The partnership is expected to implement innovative strategies that will benefit both organizations and their communities. The partnership is a significant strategic move that could enhance NRC's market position and influence its future performance.

20 Nov

4 Business Wire, 9:00 AM
National Research Corporation (NRC) has appointed David Burik as Executive Vice President of Strategic Insights. Burik brings over 20 years of experience in healthcare analytics and consulting, previously serving in leadership roles at various organizations. His expertise is expected to enhance NRC's strategic initiatives and drive growth in the healthcare sector. The appointment of a seasoned executive like David Burik is likely to significantly impact NRC's strategic direction and market positioning.

13 Nov

4 Business Wire, 9:00 AM
NRC Health has partnered with BJC HealthCare to enhance patient experience across their unified network. This collaboration aims to leverage NRC's expertise in patient experience measurement and improvement, enabling BJC to better understand and respond to patient needs. The partnership is expected to drive innovation in healthcare delivery and improve overall patient satisfaction. The partnership is a significant strategic move that could enhance NRC's competitive positioning and market performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us